Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110486 · ClinicalTrials.gov registry record · Phase 1
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
A Phase 1 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 102
- Enrollment target
NCT01110486 is a Phase 1 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 102 participants.
The verdict
NCT01110486, a Phase 1 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with carboplatin or docetaxel.
Interventions
- DRUG ABT-348
- DRUG ABT-348 and carboplatin
- DRUG ABT-348 and docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2010-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110486
The ClinicalTrials.gov registry entry for NCT01110486 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ABT-348 is the first listed.
NCT01110486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01110486 about?
NCT01110486 is a clinical study titled "ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors". The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with carboplatin or docetaxel.
What is the current status of trial NCT01110486?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2010-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01110486?
The interventions under investigation include: ABT-348 (DRUG), ABT-348 and carboplatin (DRUG), ABT-348 and docetaxel (DRUG).
Who is sponsoring clinical trial NCT01110486?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.